ANGPTL4 and coronary artery disorder: Rare variant analyses have provided examples on how genetic discoveries can point to therapeutic approaches for CAD, e.g., inhibition of HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) (28), PCSK9 (proprotein convertase subtilisin/kexin type 9) (29), and ANGPTL4 (angiopoietin-like 4) (30).